NCT01970865 2024-08-12
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01712217 2024-08-02
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02584634 2023-07-07
Javelin Lung 101
Pfizer
Phase 1/2 Terminated
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04292119 2021-03-10
Lorlatinib Combinations in Lung Cancer
Massachusetts General Hospital
Phase 1/2 Unknown